LGND Live signals | Maximize Profits with Getagraph.com

SELL 137211 min ago

@ $73.34

Issued: 14 Feb 2024 @ 10:26

Return: 17.34%

Previous signal: Feb 13 - 09:30

Previous signal: Buy

Return: -1.89 %

Live Chart Being Loaded With Signals

Commentary (17 May 2024 @ 16:00):

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide...

Stats
Today's Volume	100 217
Average Volume	186 907
Market Cap	1.55B
EPS	$0 ( 2024-05-07 )
Next earnings date	( $0 ) 2024-08-06
Last Dividend	$0.456 ( 2010-07-02 )
Next Dividend	$0 ( N/A )
P/E	16.09
ATR14	$0.0800 (0.09%)

Insider Trading

Date	Person	Action	Amount	type
2024-05-09	Gray Nancy Ryan	Sell	934	Common Stock
2024-05-17	Espinoza Octavio	Buy	5 022	Common Stock
2024-05-15	Espinoza Octavio	Sell	5 873	Common Stock
2024-05-17	Espinoza Octavio	Buy	145	Common Stock
2024-05-17	Espinoza Octavio	Sell	5 022	Common Stock

INSIDER POWER
55.20
Last 99 transactions
Buy: 561 574 \| Sell: 144 779

Volume Correlation

Long: 0.09 (neutral)

Short: -0.72 (moderate negative)

Signal:(58.537) Neutral

Ligand Pharmaceuticals Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Ligand Pharmaceuticals Correlation - Currency/Commodity

0.30
( neutral )

0.35
( neutral )

-0.65
( weak negative )

0.11
( neutral )

-0.62
( weak negative )

0.65
( weak )

Ligand Pharmaceuticals Financials

Annual	2023
Revenue:	$131.31M
Gross Profit:	$119.75M (91.20 %)
EPS:	$3.02

FY	2023
Revenue:	$131.31M
Gross Profit:	$119.75M (91.20 %)
EPS:	$3.02

FY	2022
Revenue:	$196.25M
Gross Profit:	$143.42M (73.08 %)
EPS:	$-0.310

FY	2021
Revenue:	$277.13M
Gross Profit:	$214.96M (77.56 %)
EPS:	$2.22

Financial Reports:

No articles found.

Ligand Pharmaceuticals Dividends

(Q3/22)	(Q4/22)	(Q1/23)	(Q2/23)	(Q3/23)	(Q4/23)	(Q1/24)	(Q2/24)	(Q3/24)	(Q4/24)
$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)	$0 (N/A)

Ligand Pharmaceuticals Dividend Information - Ex Dividend Junior

Dividend Sustainability Score: 9.60 - good (96.02%) | Divividend Growth Potential Score: 3.73 - No dividend growth expected in the near future

Information

First Dividend	$9.36	2007-04-03
Last Dividend	$0.456	2010-07-02
Next Dividend	$0	N/A
Payout Date	0000-00-00
Next Payout Date	N/A
# dividends	2	--
Total Paid Out	$9.81	--
Avg. Dividend % Per Year	0.00%	--
Score	2.22	--
Div. Sustainability Score	9.60
Div.Growth Potential Score	3.73
Div. Directional Score	6.67	--

Next Divdend (Est)
(2026-09-30)

$0 Estimate 0.00 %

Dividend Stability

0.01 Very Bad

Dividend Score

2.22

Pay Frequency

Sporadic

Yearly Payout

Year	Amount	Yield
2007	$9.36	14.30%
2008	$0	0.00%
2009	$0	0.00%
2010	$0.456	3.50%
2011	$0	0.00%
2012	$0	0.00%
2013	$0	0.00%
2014	$0	0.00%
2015	$0	0.00%
2016	$0	0.00%
2017	$0	0.00%
2018	$0	0.00%
2019	$0	0.00%
2020	$0	0.00%
2021	$0	0.00%
2022	$0	0.00%
2023	$0	0.00%
2024	$0	0.00%

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. On the whole, the dividend outlook remains neutral, meriting close observation of both the company's financial health and growth prospects.

Top 10 dividend Companies for NASDAQ

Symbol	Title	Last dividend	Frequency	Years Dividend	Yearly Dividend	Score
QYLD	Dividend Royal	2023-11-20	Monthly	11	7.50%	8.50
PSEC	Dividend Royal	2023-12-26	Monthly	21	7.04%	8.50
SLVO	Dividend Royal	2023-11-20	Monthly	12	10.77%	8.50
OXLC	Dividend Diamond	2023-12-14	Monthly	14	10.00%	8.50
GAIN	Dividend Royal	2023-12-04	Monthly	20	8.19%	8.50
OXSQ	Dividend Royal	2023-12-14	Monthly	21	9.10%	8.50
GLDI	Dividend Royal	2023-11-20	Monthly	12	7.15%	8.50
HRZN	Dividend Royal	2023-12-18	Monthly	15	6.60%	8.45
USOI	Dividend Royal	2023-11-20	Monthly	8	16.70%	8.28
PFLT	Dividend King	2023-11-15	Monthly	14	6.50%	8.27

Dividend Sustainability Score (DSS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
netProfitMarginTTM	0.793	1.500	10.00	10.00	[0 - 0.5]
returnOnAssetsTTM	0.103	1.200	6.58	7.89	[0 - 0.3]
returnOnEquityTTM	0.132	1.500	9.64	10.00	[0.1 - 1]
payoutRatioTTM	0	-1.000	0	0	[0 - 1]
currentRatioTTM	20.70	0.800	10.00	8.00	[1 - 3]
quickRatioTTM	19.03	0.800	10.00	8.00	[0.8 - 2.5]
cashRatioTTM	2.81	1.500	10.00	10.00	[0.2 - 2]
debtRatioTTM	0.00678	-1.500	9.89	-10.00	[0 - 0.6]
interestCoverageTTM	-1.073	1.000	-1.508	-1.508	[3 - 30]
operatingCashFlowPerShareTTM	1.935	2.00	9.35	10.00	[0 - 30]
freeCashFlowPerShareTTM	-0.971	2.00	-0.486	-0.971	[0 - 20]
debtEquityRatioTTM	0.00768	-1.500	9.97	-10.00	[0 - 2.5]
grossProfitMarginTTM	0.849	1.000	10.00	10.00	[0.2 - 0.8]
operatingProfitMarginTTM	-0.0209	1.000	-2.42	-2.42	[0.1 - 0.6]
cashFlowToDebtRatioTTM	5.54	1.000	10.00	10.00	[0.2 - 2]
assetTurnoverTTM	0.129	0.800	-2.47	-1.976	[0.5 - 2]
Total Score				9.60

Dividend Growth Score (DGS)

Ratio	Actual Value	Weight	Normalized Value	Score	Range
peRatioTTM	16.26	1.000	8.46	0	[1 - 100]
returnOnEquityTTM	0.132	2.50	9.77	10.00	[0.1 - 1.5]
freeCashFlowPerShareTTM	-0.971	2.00	-0.324	-0.971	[0 - 30]
dividendYielPercentageTTM	0	1.500	0	0	[0 - 0.4]
operatingCashFlowPerShareTTM	1.935	2.00	9.35	10.00	[0 - 30]
payoutRatioTTM	0	1.500	0	0	[0 - 1]
pegRatioTTM	1.573	1.500	2.85	0	[0.5 - 2]
operatingCashFlowSalesRatioTTM	0.290	1.000	5.25	0	[0.1 - 0.5]
Total Score				3.73

Ligand Pharmaceuticals Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Ligand Pharmaceuticals

Ligand Pharmaceuticals Incorporated, a biopharmaceutical company, focuses on developing or acquiring technologies that help pharmaceutical companies to discover and develop medicines worldwide. Its commercial programs include Kyprolis and Evomela, which are used to treat multiple myeloma; Veklury for the treatment of moderate or severe COVID-19; Teriparatide injection product for osteoporosis; Vaxneuvance for the prevention of invasive disease caused by Streptococcus pneumoniae; and Pneumosil, a pneumococcal conjugate vaccine to help fight against pneumococcal pneumonia among children. The company also offers Rylaze, a recombinant erwinia asparaginase for the treatment of acute lymphoblastic leukemia or lymphoblastic lymphoma in adult and pediatric patients; and Nexterone, a captisol-enabled formulation of amiodarone; and Zulresso, a captisol-enabled formulation of brexanolone for the treatment of postpartum depression. In addition, it provides Noxafil-IV, a captisol-enabled formulation of posaconazole for IV use; Duavee for the treatment of postmenopausal osteoporosis; Aziyo portfolio of commercial pericardial repair and CanGaroo envelope extracellular matrix products; Exemptia for autoimmune diseases; Vivitra for breast cancer; Bryxta and Zybev for various indications; and Minnebro for the treatment of hypertension. The company's partners and licenses programs, which are in clinical development used for the treatment of cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver and kidney disease, and other diseases. Further, it sells Captisol materials. The company was incorporated in 1987 and is headquartered in Emeryville, California.